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Adipose tissue plays a key role in the development of insulin resistance and its pathological 
sequelae, such as type 2 diabetes and non-alcoholic fatty liver disease. Dysfunction 
in the adipose tissue response to storing excess fatty acids as triglyceride can lead to 
adipose tissue inflammation and spillover of fatty acids from this tissue and accumulation 
of fatty acids as lipid droplets in ectopic sites, such as liver and muscle. Extracellular 
vesicles (EVs) are released from adipocytes and have been proposed to be involved in 
adipocyte/macrophage cross talk and to affect insulin signaling and transforming growth 
factor β expression in liver cells leading to metabolic disease. Furthermore EV produced 
by adipose tissue-derived mesenchymal stem cells (ADSC) can promote angiogenesis 
and cancer cell migration and have neuroprotective and neuroregenerative properties. 
ADSC EVs have therapeutic potential in vascular and neurodegenerative disease and 
may also be used to target specific functional miRNAs to cells. Obesity is associated with 
an increase in adipose-derived EV which may be related to the metabolic complications 
of obesity. In this review, we discuss our current knowledge of EV produced by adipose 
tissue and the potential impact of adipose tissue-derived EV on metabolic diseases 
associated with obesity.
Keywords: adipocytes, extracellular vesicles, adipose-derived mesenchymal stem cells, differentiation, insulin 
resistance, non-alcoholic fatty liver disease
iNTRODUCTiON
Over the last few decades adipose tissue and adipocyte function has been under extensive study due 
to their central role in energy homeostasis, obesity, and diabetes (1, 2). The discovery of adipokines 
has led to the recognition of the key role of adipose tissue secretory products in mediating the 
consequences of excess adipose tissue accumulation and its wider role in metabolism. More recently, 
adipose tissue secretion of extracellular vesicles (EVs) and their potential role in the regulation of 
metabolism and the development of insulin resistance (IR) and type 2 diabetes has come under 
investigation. This article will review the data available on the nature of the EV produced by the 
component parts of adipose tissue and their potential local and remote end-organ effects.
Extracellular vesicles are spherical vesicles with an outer lipid bilayer which are released from 
almost all living cells from bacteria to multicellular organisms (3). EVs are classified according to 
their size and the pathway by which they were produced (i.e., endocytic or plasma membrane). EVs 
are grouped by size and origin as exosomes (~40–100 nm), microvesicles (~100–1,000 nm), and 
FigURe 1 | White adipocyte and ADSC-derived EV. Abbreviations: EV, extracellular vesicle; ADSC, adipose tissue-derived mesenchymal stem cells; IR, insulin 
resistance; TGF, transforming growth factor; T2DM, type 2 diabetes mellitus; CVD, cardiovascular disease; NAFLD, non-alcoholic fatty liver disease.
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apoptotic bodies (~1,000–5,000 nm). Microvesicles and apoptotic 
bodies are formed directly via blebbing of the plasma membrane, 
whereas exosomes are produced via an endocytic pathway (4). 
It is difficult to classify EV as there is currently a lack of specific 
EV markers and there are no internationally accepted definitions 
of EV. EV may be isolated by a variety of different methods, the 
most common being differential and buoyant density gradient 
ultracentrifugation, gel filtration chromatography or other size 
separation techniques, flow cytometry, or by precipitation using 
polymers or antibodies (5). EVs play an important role in inter-
cellular communications. With a wide range of inhibitory and 
stimulatory effects, EV can influence a variety of cell functions, 
including cytokine production, cell proliferation, apoptosis, and 
metabolism (6). These effects are mediated by the content of EV 
including RNA (mRNA, miRNA, and other RNAs), protein, and 
lipids (3). The distribution of EV is widespread, and EV can be 
isolated both in vivo (mainly from body fluids, such as plasma/
serum, urine, cerebrospinal fluid, saliva, etc.) and in vitro (from 
cell-conditioned media). The composition and function of EV 
derived from adipose tissue is poorly understood but of major 
interest due to the central role of obesity in type 2 diabetes mel-
litus (T2DM).
ADiPOSe TiSSUe STRUCTURe  
AND FUNCTiON
Types of Adipose Tissue
Human white adipose tissue is distributed throughout the body 
with the main depots classified as subcutaneous adipose tissue 
and visceral adipose tissue (7). Eighty percent of white adipose 
tissue is located in the subcutaneous compartment and up to 
10–20% is located in the visceral compartment, mainly around 
the mesentery and omentum (7). There are also small quanti-
ties of adipose tissue located around blood vessels (perivascular 
adipose tissue) and in liver, muscle, joints, and bone marrow. 
While subcutaneous adipose tissue functions predominately 
benignly as a storage depot for excess fatty acids, visceral adi-
pose tissue is more closely linked to the adverse metabolic and 
inflammatory profile observed in individuals with obesity and 
IR (8–10). Brown adipose tissue stores are substantial in rodents 
but in humans are mainly only found in infants or in adults 
who have undergone cold adaptation (11). Brown adipose tis-
sue promotes non-shivering thermogenesis via the expression 
of uncoupling protein 1 in its mitochondrial membranes and 
may have an important role in energy homeostasis (12). White 
adipose tissue can be induced to express some of the features of 
brown adipose tissue and the resultant adipocytes are termed 
beige (13).
Cellular Composition of Adipose Tissue
Adipose tissue comprises adipocytes and adipose-derived stro-
mal cells (Figure 1). Adipocytes are the main cell type in adipose 
tissue. Excess calories, as fatty acids, are stored in lipid droplets 
within adipocytes in the form of triglyceride. In the postprandial 
period, newly formed, smaller adipocytes more avidly take up 
free fatty acids released from circulating triglyceride in plasma 
lipoproteins by lipoprotein lipase resulting in the produc-
tion of larger adipocytes (14). Adipose stromal cells comprise 
pre-adipocytes, endothelial cells, fibroblasts, lymphocytes, 
macrophages, myeloid cells, pericytes, smooth muscle cells, and 
mesenchymal stromal stem cells (15). Adipose stromal cells sup-
port the proliferation and the differentiation of pre-adipocytes to 
adipocytes in vivo and in vitro and secrete a variety of cytokines 
and growth factors exerting potential paracrine effects (15). 
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adipose tissue-derived mesenchymal stem cells (ADSC) are 
multipotent and can differentiate into adipocytes, osteoblasts, 
chondrocytes, and myocytes (16).
Adipose Tissue expansion
When individuals become obese, their excess calorific intake is 
stored in the form of triglycerides within the adipocytes of white 
adipose tissue. If there is insufficient capacity in mature adipo-
cytes, new adipocytes are formed from pre-adipocytes in order 
to increase storage capacity (17). The formation of adipocytes 
(adipogenesis) occurs in two phases (18). The first phase of white 
adipose tissue adipogenesis is committed to differentiation and 
involves the production of committed white pre-adipocytes from 
mesenchymal stem cells. Once committed, pre-adipocytes lose 
their multi-potency and can only differentiate into adipocytes 
or proliferate. Terminal differentiation to form mature white 
adipocytes results in the characteristic appearance of the mature 
adipocyte containing one single lipid droplet that occupies almost 
all the space within the cell. Similarly, brown adipose tissue dif-
ferentiation comprises a committed differentiation step followed 
by a terminal differentiation step (18).
In some individuals, there appears to be a limited ability to 
produce mature adipocytes from pre-adipocytes (hyperplasic 
adipocyte expansion) and instead excess fatty acids are stored 
in existing mature adipocytes leading to an increase in their size 
(hypertrophic expansion) (19). Larger adipocytes tend to be more 
dysfunctional, and they become insulin resistant resulting in 
increased lipolysis due to resistance to the anti-lipolytic effects of 
insulin (8). Failure of angiogenesis and provision of an adequate 
blood supply to hypertrophic adipocytes leads to necrosis, mac-
rophage infiltration into adipose tissue and inflammation and 
adipokine release. “Spillover” of fatty acids unable to be retained 
in subcutaneous adipocytes leads to an increase in the visceral 
fat compartment and eventually flux of fatty acids into ectopic 
sites, stored as intracellular lipid droplets in tissues, such as liver 
and the pancreas. The formation of ectopic fat is closely linked to 
the development of IR and T2DM, and individuals with limited 
adipocyte expandability, such as South Asians, are at increased 
risk of type 2 diabetes (20).
evs FROM ADiPOCYTeS
Composition of Adipocyte evs
Extracellular vesicle production has been studied in whole adi-
pose tissue explants (subcutaneous and visceral) (21, 22), isolated 
adipocytes, in vitro differentiated adipocytes (21) and in ADSC 
(see later). Kranendonk et  al. (21) characterized EV isolated 
by differential ultracentrifugation from ex vivo subcutaneous 
and visceral adipose tissue explant cultures and from human 
adipocytes differentiated in vitro from Simpson Golabi Behmel 
Syndrome (SGBS) pre-adipocytes (23). Both adiponectin-positive 
and adiponectin-negative EVs were produced by whole adipose 
tissue, as determined by flow cytometry and could be separated 
by differential ultracentrifugation (21). The authors suggested 
that adiponectin-positive EV came specifically from adipocytes, 
rather than stromal cells (21). Differentiated human adipocytes 
produced EV containing the presumed adipose-specific markers 
FABP-4 and adiponectin as well as a number of inflammatory 
adipokines, including MIF, TNFα, MCSF, and RBP-4 (21). 
Adipokine profile differed between subcutaneous adipose tissue 
EV and visceral adipose tissue EV with concentrations of IL-6, 
MIF, and MCP-1 significantly higher in visceral adipose tissue 
EV compared to those from subcutaneous adipose tissue (24). 
The exosome miRNA profile from lean and obese individuals was 
compared and 55 differentially expressed miRNA were found (25). 
The differentially expressed miRNAs identified were predicted to 
regulate the transforming growth factor (TGF)β-signaling and 
wnt/β-catenin signaling pathways (25). A differential EV prot-
eomic profile has also been observed between obese diabetic and 
obese non-diabetic rats (26).
Extracellular vesicle production by adipocytes has also been 
studied in the mouse 3T3-L1 pre-adipocyte cell line which can 
be differentiated to mature adipocytes (27). EV concentration 
across a size range of 0–1,000 nm was measured by nano-tracking 
analysis and concentrations of all particle sizes were more than 
threefold higher prior to adipogenesis (27). Higher particle 
concentrations were particularly observed for particles less than 
300 nm. Lipid composition of EV was different after adipogenesis 
with higher membrane phosphatidyl serine content and a higher 
proportion of arachidonic acid (27). There was no change in 
EV protein marker expression (CD9, CD63, TSG101, and Alix) 
or PPARγ protein content after differentiation but FABP-4 and 
PREF-1 levels decreased while adiponectin content almost 
doubled (27). 3T3-L1 adipocyte exocytosis has been shown to be 
stimulated by cAMP via a PKA-independent pathway and this 
was regulated via both calcium-dependent and -independent 
processes (28). Exosome release from 3T3-L1 cells was increased 
by the long chain omega-3 fatty acid docosahexaenoic acid 
(29). Because of potential hypoxia in adipose tissue resulting 
from adipocyte hypertrophy, the effect of hypoxia on 3T3-L1 
differentiated adipocytes exosome production was assessed (30). 
3T3-L1 adipocytes exposed to hypoxia had a different exosome 
proteomic profile compared to control adipocyte exosomes (30). 
In particular, exosomes produced under hypoxic conditions were 
enriched in enzymes involved in de novo lipogenesis and these 
exosomes were able to promote lipid accumulation in recipient 
3T3-L1 cells.
Murine brown adipocytes produce exosomes and their pro-
duction is increased by cAMP treatment (cAMP is the second 
messenger induced by cold exposure and β-adrenergic stimula-
tion) (31). Beige, but not white, adipocyte exosome production 
was increased nearly 11-fold by treatment with cAMP (31). 
When mouse whole adipose tissue was exposed to cold, exo-
some production was also increased (31). miRNA profiling of 
the exosomes produced by murine brown adipocytes identified 
miR-92a as a specific marker that was downregulated on cold 
exposure (31). Feeding mice a high fat diet induced whitening 
of brown adipose tissue and an increase in serum miR-92a levels, 
whereas cold exposure was associated with decreased serum 
miR-92a levels. In lean humans whose brown adipose tissue 
activity was assessed by labeled glucose uptake, there was a nega-
tive correlation between brown adipose tissue activity and serum 
miR-92a levels (31). Furthermore, in 10 human subjects exposed 
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to cold acclimatization for 10 days, serum miR-92a abundance 
was decreased and the change in miR-92a levels correlated with 
the change in brown adipose tissue activity.
Functions of Adipose Tissue-Derived ev
Extracellular vesicles derived from adipose tissue may play a role 
in the paracrine cross talk between adipocytes and macrophages 
(Figure  1). EVs secreted from both subcutaneous and visceral 
adipose tissue explants and from SGBS-derived adipocytes 
were able to promote the differentiation of primary monocytes 
into macrophages. These macrophages had the same cytokine 
secretory profile as macrophages found in human adipose tissue, 
reflecting a mixed M1/M2 phenotype (21). Adiponectin-positive 
EVs were much more effective than adiponectin-negative EVs in 
effecting monocyte differentiation as were EVs derived from vis-
ceral, rather than subcutaneous tissue explants (21). Conditioned 
medium was collected from macrophages exposed to adipose 
tissue EV. When human adipocytes were then exposed to this 
conditioned macrophage medium, insulin signaling as assessed 
by Akt phosphorylation was inhibited in the adipocytes (21). 
Differentiated 3T3-L1 adipocytes when stressed by exposure to 
palmitic acid produced microparticles which could act as chemo-
attractants for monocytes and primary macrophages (32). Purified 
murine adipose tissue exosome-like vesicles when injected back 
into mice were taken up by peripheral blood monocytes which 
then differentiated into macrophages secreting TNFα and IL-6 
(33). When exosome-like vesicles produced by ob/ob mice, which 
have a high RBP-4 content, were injected into wild-type mice, the 
recipient mice developed IR (33). This response was less marked 
in TLR4 knockout mice (33). Taken together these data provide 
evidence that EV produced by adipocytes may communicate with 
immune cells and influence whole body IR.
Kranendonk et al. looked at the effects of subcutaneous and 
visceral adipose tissue EV on insulin signaling and expression 
of genes involved in gluconeogenesis in a hepatocyte cell line 
(HepG2) and in myotubes differentiated from a myoblast cell 
line (C2C12) (24). There was a mixed response to individual 
adipose tissue EV preparations in hepatocytes. Adipose tissue EV 
from the majority of individuals inhibited Akt phosphorylation 
while adipose tissue EVs from a few individuals stimulated Akt 
phosphorylation. There was no effect of either subcutaneous or 
visceral adipose tissue EV on myotube insulin signaling. After 
exposure of hepatocyte cells to subcutaneous and visceral adipose 
tissue EV, there was a negative association between Akt signal-
ing and glucose-6-phosphatase gene expression (24). Exosomes 
produced by visceral adipose tissue explants from obese humans 
can integrate into HepG2 cells and hepatic stellate cell lines 
(22). Gene expression profiling of HepG2 cells exposed to these 
exosomes indicated dysfunctional extracellular matrix regulation 
in HepG2 cells and dysregulation of the TGFβ signaling pathways 
in both HepG2 and hepatic stellate cell lines (22). The authors 
proposed that in vivo these changes may induce liver fibrosis and 
may link obesity to non-alcoholic fatty liver disease (22). Similar 
observations were only made at high doses of visceral adipose 
tissue exosomes from a single lean individual but it is hard to 
draw conclusions regarding differences between exosomes from 
lean and obese individuals from this single experiment (22).
Adipocytes can be found in the tumor microenvironment and 
have been shown to promote tumor progression (34). Obesity is 
a risk factor for melanoma and its malignant progression. In a 
study of human subcutaneous adipocyte exosomes isolated by dif-
ferential ultracentrifugation (35), there was a correlation between 
adipose tissue exosome shedding and donor BMI. When used 
at equal concentrations, exosomes from overweight and obese 
donors increased melanoma migration more than exosomes 
from lean individuals in a dose-dependent manner (35). This 
effect was thought to be mediated via fatty acid oxidation as 
inhibition by etomoxir reversed the effect (35). Interestingly, 
exosomes produced by mature 3T3-F442A adipocytes were 
found by mass spectrometry to contain an abundance of proteins 
involved in lipid metabolism, particularly those involved in fatty 
acid oxidation (35).
Adipocyte ev and whole Body  
Metabolic Status
Circulating EV levels have been linked to cardiovascular disease 
(CVD), diabetes, and non-alcoholic fatty liver disease (33, 36, 37) 
but the extent to which circulating EV derived from adipose tissue 
are involved is uncertain. Circulating EVs positive for CD9 and 
adiponectin have been isolated from the plasma of patients with 
aortic aneurysm (24) raising the possibility that adipose tissue 
may communicate with other organs via EV release. Obesity is a 
risk factor for CVD, type 2 diabetes and non-alcoholic fatty liver 
disease and may be associated with either higher EV release from 
adipose tissue stores or release of EV with a different functional-
ity (22, 25, 26, 35) with downstream metabolic consequences for 
end organs involved in these diseases (Figure 1). The difficulty 
is being confident about which specific markers identify EV 
from adipose tissue. As discussed above, cellular experiments 
have suggested adiponectin, FABP-4, and RBP-4 to be adipocyte 
EV-specific markers. Proteomic profiling of extensively purified 
human plasma exosomes identified the presence of PPARγ, a key 
transcription factor in adipocyte differentiation (38). However, 
since this protein can also be expressed in vascular endothelial 
cells and immune cells, this cannot categorically identify adipose 
tissue as a source of plasma EV. Similarly for adiponectin, it has 
been suggested that exosomes only account for a minor propor-
tion of the total adiponectin secreted from 3T3-L1 cells (29) and, 
thus, it may not be a reliable marker for plasma EV. Others using 
mouse whole body models have suggested that perilipin A can act 
as an adipocyte EV marker (32, 39). The lack of definitive data on 
this issue makes it difficult to interpret experiments on circulating 
EV proposed to be from adipose tissue and the following data 
should be viewed with caution.
The number of visceral, but not subcutaneous, ex vivo adipose 
tissue-derived EV per gram of fat, quantified by flow cytometry, 
correlated with whole body HOMA-IR (but not body mass index 
or hsCRP levels) in patients (n = 11) with aortic aneurysm from 
whom the adipose tissue biopsies were collected (21). In a similar 
study, subcutaneous adipose tissue EVs produced from 16 indi-
viduals were inversely correlated with waist circumference and 
presence of metabolic syndrome, while visceral adipose tissue EV 
correlated positively with plasma liver enzymes (24).
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Circulating adipose microparticles, as determined by the 
presence of perilipin A, from ob/ob mice resulted in activation 
of monocytes in the circulation and in adipose tissue of wild-
type mice (32). Perilipin A-positive EVs are higher in mice with 
diet-induced obesity and in humans with metabolic syndrome 
(39). In humans, circulating perilipin A-positive EV could be 
reduced by a 3-month low calorie dietary intervention. Using 
FABP-4 as a marker of adipocyte-derived circulating exosomes, 
the change in adipocyte-derived exosome miRNA profile a 
year after gastric bypass surgery was assessed (40). Changes 
in miRNA profile that were predicted to regulate the insulin 
signaling pathway were observed and the degree of change in 
miRNA profile linked was correlated with both the change in 
IR as assessed by HOMA and the change in plasma levels of 
branched chain amino acids (40).
In a larger study of 1,012 patients with vascular disease, plasma 
EV were isolated by precipitation and characterized by multiplex 
immunoassay (41). Microvesicles containing the proteins cysta-
tin C and CD14 have previously been shown to be associated with 
atheroma plaque size, and increased risk of CVD morbidity and 
mortality (42). The relationship between levels of these cystatin 
C positive and CD14-positive EV with subcutaneous and visceral 
adipose tissue thickness and metabolic disease prevalence and 
incidence was assessed. High EV-cystatin C levels were associ-
ated with high plasma hsCRP and low HDL-cholesterol (41). 
HDL-cholesterol was positively associated with EV-CD14 levels 
(41). EV-cystatin C levels were associated with increased odds of 
metabolic syndrome (OR 1.57; 95% CI 1.19–2.17); however, there 
was no relationship between EV-cystatin-C levels and obesity or 
whole body IR (41). By contrast, EV-CD14 were associated with 
reduced hazard of developing type 2 diabetes (HR 0.84, 95% CI 
0.75–0.94) over a 6.5  years follow-up (41). Again it is difficult 
to know whether these EV risk markers are actually produced 
by adipose tissue. EV-cystatin C and EV-C14 are released by 
monocytes, endothelial cells, and platelets; but while CD14 
adipose tissue gene expression and cystatin C protein secretion 
(43) is increased in adipose tissue from obese humans, there is 
no direct evidence that these proteins are secreted in EV from 
adipose tissue.
ADiPOSe TiSSUe-DeRiveD 
MeSeNCHYMAL STeM CeLLS (ADSC)
There is great interest in adipose tissue as a source of stems cells 
for regenerative medicine for use in cancer and other diseases. 
Beneficial effects of such treatments may result from paracrine 
effects of ADSC mediated by EV. Exosomes produced by ADSC 
isolated from human adipose tissue have been shown to contain 
small RNA species predominately miRNA and snoRNA with 
some evidence that tRNA species are enriched (44). It appears 
that the contents do not merely reflect the source cellular content 
but that some RNA species are preferentially released (44). There 
is evidence that the protein secretory profile of ADSC differs 
from individual to individual and that raises the possibility that 
ADSC comprise a heterogeneous population of cells of function-
ally different subtypes and may produce corresponding EV (45). 
There are also data to suggest that functional aspects of ADSC 
differ from stem cells derived from other tissues (46). EVs from 
ADSC have been considered as a delivery route for delivering 
therapeutic miRNA to diseased cells.
ADSC ev in Cancer
Adipose tissue-derived mesenchymal stem cells were isolated 
from abdominal fat from patients undergoing neoplastic urologi-
cal surgery and from participants without cancer (47). miRNA 
profiling of exosomes from these ADSC showed that, in both can-
cer and non-cancer patients, some exosome and ADSC miRNA 
content was similar. However, there did appear to be selective 
enrichment of some miRNA (let-7-a-1, miR-21, and miR-1260b) 
into exosomes (47). ADSC transfected with a miR-122 expres-
sion plasmid secreted exosomes containing miR-122. When the 
miR-122-containing exosomes were added to hepatocellular 
carcinoma cells, the cells became sensitive to chemotherapeutic 
drugs (48). Furthermore, intra-tumoural injection of transfected 
ADSC EV exosomes increased the effectiveness of an anti-cancer 
agent on hepatocellular carcinoma in an in  vivo mouse model 
(48). ADSC exosomes have also been shown to promote migra-
tion of a breast cancer cell line (MCF7) (49).
ADSC ev in vascular Disease
One study has compared EV produced by ADSC isolated from 
subcutaneous and visceral adipose tissue in obese and non-obese 
individuals (50). There was no difference in EV number or size 
between ADSC derived from non-obese or obese subjects (50). 
The content of VEGF and MMP-2 (markers of EV angiogenic 
potential) was lower in EV derived from the subcutaneous and 
the visceral compartment of obese individuals compared to 
those derived from the same compartments in non-obese indi-
viduals (50). In addition, the content of miR-126, but not that 
of miR-130A, (both pro-angiogenic miRs) was also reduced in 
EV produced by ADSC from obese individuals (50). These data 
suggesting that EV from obese ADSC, either from subcutane-
ous or from visceral depots, may have reduced pro-angiogenic 
potential were confirmed by in vitro experiments showing that 
EV from obese ADSC had reduced ability to induce migration 
and tube formation in cultured endothelial cells (50). Palmitic 
acid treatment could induce the anti-angiogenic EV changes 
in  vitro and this suggests that increased circulating fatty acids 
in human obesity may influence the function of ADSC (50). 
ADSC EV secretion was stimulated by platelet-derived growth 
factor (PDGF) and changed EV protein composition enhancing 
their angiogenic properties (51). PDGF-stimulated ADSC were 
able to promote vessel formation when injected subcutaneously 
in Matrigel into mice (51). ADSC microvesicles have also been 
shown to increase migration and tube formation by human 
umbilical vein endothelial cells (52). The active agent carried in 
the microvesicles was thought to be miR-31 that inhibited factor-
inhibiting HIF-1 (52).
Restenosis of vein grafts is a particular problem with coronary 
artery bypass surgery. ADSC have been used to try and reduce 
neointimal hyperplasia in vein grafts. Human ADSC were shown, 
by in vitro cell culture and in a mouse model, to reduce vein graft 
neointima formation by inhibiting vascular smooth muscle 
cell proliferation and migration and reducing macrophage 
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migration and inflammation (53). ADSC also inhibit the 
 activation,  differentiation, and proliferation of T cells (54). In a 
porcine model of metabolic syndrome and renal artery stenosis, 
treatment with autologous EV from ADSC resulted in decreased 
renal inflammation and increased kidney blood flow and glo-
merular filtration rate (55). Others have found that a combined 
treatment of ADSC plus ADSC-derived exosomes had superior 
ability, compared to either one alone, to protect the kidney from 
acute ischemia–reperfusion injury in a rat model (56).
ADSC and Neurodegenerative Disease
ADSC are also of interest for the treatment of neurodegenerative 
disorders such as amyotrophic lateral sclerosis (57). Murine ADSC 
exosomes protect motor neurone-like NSC-34 cells from oxidative 
damage increasing their viability (57) and similarly human ADSC 
exosomes protect neurones against glutamate-induced damage 
(58). Others have shown in mice in vitro that ADSC nanovesicles 
and microvesicles prevented apoptosis in neuronal cells and 
increased remyelination in cerebellar slices demyelinated using 
lysophosphatidyl choline (59). Again EV have been considered as 
a delivery vehicle with therapeutic implications for neurodegen-
erative disease. ADSC secreted exosomes containing neprilysin, 
a major β-amyloid peptide degrading enzyme, and the exosomes 
were capable of delivering this protein to a neuroblastoma cell line 
(N2a) resulting in decreased secreted and intracellular β-amyloid 
peptide (60). Therefore, there is therapeutic potential for such EV 
in Alzheimer’s disease. Furthermore, exosomes from ADSC have 
been shown to have therapeutic potential in an in vitro mouse 
neuronal cell model of Huntington’s disease (61).
CONCLUSiON
Adipose tissue can produce EV from both adipocytes and ADSC 
(Figure  1). The early data presented above indicate that the 
adipose depot from which adipocyte EV are derived, and the 
relative state of obesity of the donor may influence the function 
of such EV. We are still at the first stages of research. No definitive 
marker of adipocyte-derived EV has yet been agreed upon nor 
has a consensus characteristic EV cargo been identified. This 
makes it difficult to interpret data on circulating EV in obesity 
and metabolic diseases such as type 2 diabetes. Although the 
data do suggest that circulating EV profiles change in obesity and 
metabolic disease, it is not yet clear whether EVs act merely as a 
marker of disease or whether they play a functional role in tissue 
to tissue communication. Initial cell culture and animal model 
experiments do suggest that there is the potential for commu-
nication between adipocytes and immune and liver cells via EV. 
Adipose tissue has also proved to be a source of stem cells and 
EV produced by ADSC appear to have potential roles in cancer, 
angiogenesis, vascular disease, and neurodegenerative disease, 
both as a direct effector to promote or prevent pathogenesis 
and as a delivery system to target beneficial miRNA to cells as a 
therapeutic option.
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